The clinical consequences of sucrase-isomaltase deficiency

The linked disaccharidase, sucrase-isomaltase, is a glycoprotein localized to the brush border membrane of small intestinal villi. Sucrase-isomaltase is synthesized and assembled in the rough endoplasmic reticulum as a homologous pro-enzyme dimer which passes through the Golgi apparatus and is transported to the apical cell surface of villi [1]. There, it is cleaved into its mature subunits, sucrase and isomaltase, by pancreatic proteases. Isomaltase cleaves branched (1–6 linked) α-limit dextrins, while sucrase digests sucrose, maltose, short 1–4 linked glucose oligomers, and some branched starches into sugar monomers for intestinal absorption, its activity often overlapping with maltase-glucoamylase [2]. The cleaved monosaccharides are then transported across the epithelial brush border for absorption and metabolism. Sucrase is an inducible enzyme in early development, such that increased exposure to sucrose, or the stress of doing so, increases sucrase activity [3–7].

Since the discovery of the initial trafficking error, other phenotypes have been discovered [12] and, currently, seven phenotypes are known [13]. More than 25 mutations within the human sucrase gene are responsible for these CSID phenotypes [14]. Some sucrase-isomaltase variants show classical autosomal recessive homozygous inheritance, while others demonstrate compound heterozygote inheritance [15]. Sucrase-isomaltase variants can occur on either sucrase or isomaltase subunits, resulting in varied effects on sucrase-isomaltase enzyme activity [16].

There is now strong evidence that heterozygous carriers also experience symptoms of CSID, such as chronic diarrhea, abdominal pain, and bloating [17]. It is currently estimated that 2–9 % of Americans of European descent may be affected, suggesting that sucrase-isomaltase deficiency has been greatly underrecognized [17]. Therefore, the newer term genetic sucrase-isomaltase deficiency (GSID) should be used to encompass the entire range of inheritance patterns while CSID is reserved to specifically identify homozygous recessive individuals.

For example, the sucrase-isomaltase variants V577G and G1073D result in blocked transport in the ER loss of normal enzyme activity while the sucrase-isomaltase variant V15F has reduced cell surface expression resulting in decreased sucrase activity [16]. Analyses at the cellular, molecular, and functional levels of 11 novel cases with CSID revealed three categories of sucrase-isomaltase variants: transport competent, partially transport competent, and transport incompetent [18]. Patients with all three variant categories showed reduced or drastically reduced enzymatic activities of sucrase and isomaltase and symptoms resembling irritable bowel syndrome [17].

Whether due to a primary (genetic) or secondary (acquired) deficiency, absent or diminished enzyme activity allows undigested sugars to accumulate in the lumen of the small intestine, resulting in the clinical effects of sucrase-isomaltase deficiency [12]. The osmotic effect of malabsorbed sugars contributes to watery, hyperosmolar diarrhea. Subsequently, other symptoms are caused by the fermentation of undigested sucrose by colonic bacterial microflora which release methane, hydrogen, and carbon dioxide causing bloating and abdominal pain [22].

Symptom severity becomes a function of residual sucrase and isomaltase activity, amount of sugar and starch consumed, extent of buffering by other foods, and gastric emptying [22]. Frequent diarrhea can be the result and also the cause of rapid small-bowel transit. The degree of fermentation of any malabsorbed carbohydrates by the colonic bacteria can also stimulate diarrhea and further lessen exposure time for existing enzymes to digest substrate [22]. Children are more susceptible to the symptoms of sucrase-isomaltase deficiency because the length of their small intestine is shorter and the reserve capacity of the colon to absorb excess luminal fluid is reduced [22]. Consequently, symptoms sometimes improve with age.

The current standard for the diagnosis of sucrase-isomaltase deficiency is to assay duodenal or jejunal mucosa biopsy specimens for lactase, sucrase, isomaltase (palatinase), and maltase activity [22, 23]. In addition to the usual histological specimens obtained at the time of upper endoscopy, several biopsies are sampled from the distal duodenum or jejunum, immediately frozen and sent to a laboratory, and assayed for enzyme activity. The standard assay is the Dahlquist method which incubates the biopsied tissue together with the appropriate substrate and measures the released glucose. Using this method, disaccharidase activity in the duodenum can be almost 40 % less than that in the proximal jejunum [24]. Additionally, the broad effectiveness of SI in digesting 1,4-linkages results in a tight correlation of sucrase activity with maltase and isomaltase activity [25].

The invasiveness of obtaining biopsies for disaccharidase assays has led to the development of surrogate methods, based on the exhalation of gases produced by the enzymatic degradation of the substrate which reflect the clinical effect of sucrose intolerance. The sucrose hydrogen breath test is easily performed by having the patient drink a standard amount of sucrose or ¹³C-sucrose. The amount of expired hydrogen or ¹³C-methane measured in expired breath correlates well with intestinal enzyme activity [26]. More recently, sucrase-isomaltase exome genetic sequencing has become available for identifying homozygous and compound heterozygote mutations responsible for genetic sucrase-isomaltase deficiency [16]. Additionally, dietary modification and oral enzyme replacement trials using synthetic sucrase (sacrosidase) have been employed to determine if they can clinically alleviate symptoms of sucrase-isomaltase deficiency [22, 23].

A retrospective study assessed levels of disaccharidase activity in mucosal biopsy tissue samples referred to a large gastrointestinal specialty laboratory over a 6-year period (N = 27,875) [27]. These specimens, most of which were collected during pediatric endoscopies, revealed at least one disaccharidase deficiency in 45 % of samples. Among these, 21 % were sucrase deficient, indicating that 9.3 % of the specimens showed low sucrase activity.

Subsequently, a prospective pilot study assessed the prevalence of disaccharidase abnormalities in children with recurrent abdominal pain undergoing upper endoscopy (esophagogastroduodenoscopy (EGD)) (N = 28). Among them, 15 (53.6 %) had low lactase levels, 4 (14.3 %) had low sucrase levels, 5 (17.9 %) had low maltase, and 4 (14.3 %) had low glucoamylase activity. Clinical characteristics did not correlate with the degree of disaccharidase deficiency [28]. More recently, a retrospective review studied 963 symptomatic children undergoing upper endoscopy and disaccharidase testing. Among those, 73 (7.6 %) were sucrase deficient, defined as enzyme activity <25 μmol/min/g. Only 4 children (5 %) had isolated sucrase-isomaltase deficiency, with the others also having lactase deficiency or pan-disaccharidase deficiency when all enzymes were measured (n = 44; 60 %). Abnormal biopsies were found in 33 children (45 %). Most had abdominal pain (n = 49; 78 %) and/or diarrhea (n = 27; 43 %). The final diagnosis for these 73 patients is shown in Fig. 1. It is important to note, however, that even though disaccharidase deficiencies were found on biopsy, the attending physician may not have accepted the deficiency as the primary diagnosis [25].

Thus, there is still concern that the cited studies underestimate the prevalence and only comprise a limited view of SID. In a study of 65 children diagnosed with GSID, 53 reported the onset of symptoms before 1 year of age; however, only 17 were diagnosed by that time and 30 were not diagnosed until 5 years of age [19]. While some are correctly diagnosed, many others may be missed due to dietary elimination of high sucrose or high starch foods as food allergies or misdiagnosed as chronic nonspecific diarrhea or diarrhea-predominant irritable bowel syndrome. As a result, it is incumbent upon us to more fully understand the clinical consequences of SID. Population-based and well-controlled studies are needed to explore the relationship of the various genetic and secondary deficiencies and correlate them with their clinical manifestations and response to therapy.